Nicholas Adlard
Overview
Explore the profile of Nicholas Adlard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
223
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Murray N, Truman I, Milligan G, Modi H, Adlard N
Dermatol Ther (Heidelb)
. 2024 Nov;
14(12):3211-3227.
PMID: 39487935
Introduction: Patients with hidradenitis suppurativa (HS) experience significantly delayed diagnoses of 7-10 years from symptom onset on average, but the reasons for this remain largely unknown. This study investigated drivers...
2.
Nicholas R, Scalfaro E, Dorsey R, Angehrn Z, Banhazi J, Brennan R, et al.
Pharmacoecon Open
. 2024 Jul;
8(5):755-764.
PMID: 38990487
Introduction: Administration of intravenous (IV), high-efficacy treatments (HETs) for the treatment of multiple sclerosis (MS) poses a high resourcing and planning burden on infusion centres, resulting in treatment delays that...
3.
Riley N, Drudge C, Nelson M, Haltner A, Barnett M, Broadley S, et al.
Ther Adv Neurol Disord
. 2024 Mar;
17:17562864241239453.
PMID: 38525490
Background: Evidence from network meta-analyses (NMAs) and real-world propensity score (PS) analyses suggest monoclonal antibodies (mAbs) offer a therapeutic advantage over currently available oral therapies and, therefore, warrant consideration as...
4.
Benedict R, Vo P, Adlard N, Grennan O, Enstone A, Bridge D, et al.
Clinicoecon Outcomes Res
. 2024 Feb;
16:55-67.
PMID: 38348373
Introduction: Cognitive impairment, especially relating to cognitive processing speed, is a major cause of disability in people with multiple sclerosis (MS). Utility values are quantitative estimates of the quality of...
5.
Regnault A, Loubert A, Brennan R, Meunier J, Naujoks C, Cano S, et al.
Mult Scler J Exp Transl Clin
. 2023 Oct;
9(3):20552173231201422.
PMID: 37780483
Background: Trials of disease-modifying therapies (DMTs) for multiple sclerosis (MS) often include patients with minimal disability. Patient-reported outcome instruments used in these trials have often not captured physical and psychological...
6.
Bhan V, Clift F, Baharnoori M, Thomas K, Patel B, Blanchette F, et al.
J Comp Eff Res
. 2023 Aug;
12(9):e220175.
PMID: 37606897
The costs and consequences of initial and delayed ofatumumab treatment were evaluated in relapsing-remitting multiple sclerosis with active disease in Canada. A Markov cohort model was used (10-year horizon, annual...
7.
Samjoo I, Drudge C, Walsh S, Tiwari S, Brennan R, Boer I, et al.
J Comp Eff Res
. 2023 Jun;
12(7):e230016.
PMID: 37265062
To assess the relative efficacy of disease-modifying therapies (DMTs) for relapsing multiple sclerosis (RMS) including newer therapies (ozanimod, ponesimod, ublituximab) using network meta-analysis (NMA). Bayesian NMAs for annualised relapse rate...
8.
Tatlock S, Sully K, Batish A, Finbow C, Neill W, Lines C, et al.
Patient
. 2023 Apr;
16(4):345-357.
PMID: 37017920
Aims: The aim of this study was to explore the experiences, values and preferences of people living with relapsing multiple sclerosis (PLwRMS) focusing on their treatments and what drives their...
9.
Forsberg L, Spelman T, Klyve P, Manouchehrinia A, Ramanujam R, Mouresan E, et al.
Mult Scler J Exp Transl Clin
. 2023 Feb;
9(1):20552173231153557.
PMID: 36816812
Background: To assign a course of secondary progressive multiple sclerosis (MS) (SPMS) may be difficult and the proportion of persons with SPMS varies between reports. An objective method for disease...
10.
Vudumula U, Patidar M, Gudala K, Karpf E, Adlard N
J Med Econ
. 2022 Dec;
26(1):11-18.
PMID: 36472139
Objectives: To evaluate the impact of early (at first-line) vs delayed (3-year delay) ofatumumab initiation and long-term clinical, societal, and economic outcomes of ofatumumab vs teriflunomide in relapsing multiple sclerosis...